Refine your search
Collections
Co-Authors
- K. Matchavel
- Niranjan Joshi
- Nutan Nabar
- Rama Vaidya
- D. B. A. Narayana
- Sanjiv Shah
- Bhushan Patwardhan
- Ashok Vaidya
- Mamta Lele
- Girish Tillu
- D. B. Vaidya
- Madhura Kulkarni
- Kalpana Dhuri-Shah
- Jayashree Joshi
- Sujata Jagatap
- Deepak Dave
- Hemant Paradkar
- Jaya Gogate
- Susan Sodder
- Anand Shindikar
- Anushree Mehta
- Roda Dalal
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Raut, Ashwinikumar
- Scar Endometrioma: A Case Report
Abstract Views :201 |
PDF Views:0
Authors
Affiliations
1 Clinical Research & Integrative Medicine, MRC-KHS, K. Desai Road, Vile Parle (West), Mumbai-400054, IN
2 Niron Hospital and Research Centre, Santacruz (East), Mumbai 400098, IN
1 Clinical Research & Integrative Medicine, MRC-KHS, K. Desai Road, Vile Parle (West), Mumbai-400054, IN
2 Niron Hospital and Research Centre, Santacruz (East), Mumbai 400098, IN
Source
The Indian Practitioner, Vol 68, No 7 (2015), Pagination: 58-59Abstract
No Abstract.
- Marketed Ayurvedic Antidiabetic formulations: Labeling, Drug Information and Branding
Abstract Views :278 |
PDF Views:0
Authors
Nutan Nabar
1,
Rama Vaidya
2,
D. B. A. Narayana
3,
Ashwinikumar Raut
4,
Sanjiv Shah
4,
Bhushan Patwardhan
5,
Ashok Vaidya
4
Affiliations
1 Symbiosis International University, Pune, IN
2 Kasturba Health Society's Medical Research Centre, ICMR Advanced Centre for Reverse Pharmacology in Traditional Medicine Medical Research Center-KHS, 17, Khandubhai Desai Road, Vile Parle (West), Mumbai 400 056, IN
3 Ayurvidye Trust, Bangalore, IN
4 Kasturba Health Society's Medical Research Centre, Mumbai, IN
5 The Interdisciplinary School of Health Sciences, Pune, IN
1 Symbiosis International University, Pune, IN
2 Kasturba Health Society's Medical Research Centre, ICMR Advanced Centre for Reverse Pharmacology in Traditional Medicine Medical Research Center-KHS, 17, Khandubhai Desai Road, Vile Parle (West), Mumbai 400 056, IN
3 Ayurvidye Trust, Bangalore, IN
4 Kasturba Health Society's Medical Research Centre, Mumbai, IN
5 The Interdisciplinary School of Health Sciences, Pune, IN
Source
The Indian Practitioner, Vol 66, No 10 (2013), Pagination: 631-639Abstract
Diabetic patients, in India are known to take one or more Marketed Ayurvedic Antidiabetic Formulations (MAAF) alone or with the conventional drug/s as over the counter or through self medication. The labeling information is crucial for patient information and safety besides fulfilling the regulatory needs. for drugs from any system of medicine. The present study was aimed at to study MAAF for patient information, regulatory compliance and patient safety.The labels of 180 MAAF were analysed as to the details of brand names, dosage forms, ingredients, composition, dosage schedule and precautions. Package inserts of additional fifty three MAAFs were reviewed for the compliance.
The ingredients used in the products varied widely, as to the plants' identity, parts and extracts used and their concentrations. The dosage of the ingredients ranged from a few mgs to 2-3 gms, depending on raw herbs or extracts used. The current labels, studied for the composition details, did not clearly indicate the quantity of each ingredient to the original raw herb quantum. There was a wide variation in the way composition was printed on the label. The study shows a need for improvement in compliance to labeling regulations. There was no information about the suitability of these drug's administration in pregnancy and/or lactation.,or specific dose and drug formulation for paediatric and geriatric groups.
Brand names studied have chiefly reflected antidiabetic/Madhumehaghna activity. However, some of the brand names like Sugar Knocker, Sugar balance etc convey exaggerated claims. Drug regulators may continue to license MAAF with brand names but sanction those that could be misleading. Ayurvedic manufacturers need to consider and register their trade names under Trade Mark Registration Act to avoid duplicity and misuse of same names, across the state of India.
Keywords
Ayurvedic Antidiabetic Medicine, Ayurvedic Pharmacoepidemiology, Drug Regulation, Brand Names, Labeling and Package Inserts, MAAF.- Dengue Epidemic: Challenges and Promises
Abstract Views :188 |
PDF Views:0
Authors
Affiliations
1 Kasturba Health Society – Medical Research Centre, ICMR Advanced Centre for Reverse Pharmacology in Traditional Medicine, 17, K Desai Road, Vile Parle (W), Mumbai – 400056, IN
1 Kasturba Health Society – Medical Research Centre, ICMR Advanced Centre for Reverse Pharmacology in Traditional Medicine, 17, K Desai Road, Vile Parle (W), Mumbai – 400056, IN
Source
The Indian Practitioner, Vol 66, No 11 (2013), Pagination: 702-704Abstract
No Abstract.- Reverse Pharmacology Effectuated by Studies of Ayurvedic Products for Arthritis
Abstract Views :251 |
PDF Views:82
Authors
Affiliations
1 Medical Research Centre, Kasturba Health Society, K. Desai Road, Vile-Parle (W), Mumbai 400 056, IN
2 Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Ganeshkhind, Pune 411 007, IN
1 Medical Research Centre, Kasturba Health Society, K. Desai Road, Vile-Parle (W), Mumbai 400 056, IN
2 Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Ganeshkhind, Pune 411 007, IN
Source
Current Science, Vol 111, No 2 (2016), Pagination: 337-342Abstract
Reverse pharmacology (RP) is a trans-disciplinary path for drug discovery and development from bedside observations on drug effects to bench-side experiments. This approach generates evidence of safety and efficacy at different levels of biological organization, ranging from cell to community. Eventually the innovative integration of research methods will be translated back to the bedside as a new drug. The experiential wisdom of traditional systems like Ayurveda is scientifically explored by systematic RP. This is meant to enrich modern medicine, by the relevant application of the drug discovery sciences. The evidence by RP would also help to rationally understand Ayurveda. This article highlights how the bedside experience in arthritis has been translated by RP into evidence by defined experimental and clinical studies. There is a need to understand and apply the basic principles and practices of Ayurveda in the specific protocols and models in RP so as to truly integrate effective and safe usage for definite indications. The article also discusses the RP approach for Ayurvedic medicines used for treatment of arthritis.Keywords
Ayuveda, Integrative Medicine, Repurposing Drug, Reverse Pharmacology.Full Text
- Scope of Ayurceuticals in Integrative Antenatal Care: Challenges and Opportunities
Abstract Views :210 |
PDF Views:0
Authors
Rama Vaidya
1,
Madhura Kulkarni
1,
Kalpana Dhuri-Shah
1,
Nutan Nabar
1,
Jayashree Joshi
1,
Sujata Jagatap
1,
Deepak Dave
1,
Ashwinikumar Raut
1,
Hemant Paradkar
1,
Jaya Gogate
1,
Susan Sodder
1,
Ashok Vaidya
1
Affiliations
1 Kasturba Health Society-Medical Research Center, 17, KD Road, Vile Parle (W), Mumbai 400056, IN
1 Kasturba Health Society-Medical Research Center, 17, KD Road, Vile Parle (W), Mumbai 400056, IN
Source
The Indian Practitioner, Vol 70, No 10 (2017), Pagination: 11-16Abstract
No Abstract.- Screening of Diabetic Patients for Non-Alcoholic Fatty Liver Disease Based on Liver Indices: A Retrospective Cross-Sectional Study
Abstract Views :54 |
PDF Views:0
Authors
Affiliations
1 Senior Research Fellow, Kasturba Health Society Medical Research Centre (KHS-MRC), IN
2 Physician, KHS-MRC, IN
3 Director-Integrative Medicine and Clinical Research, KHS-MRC, IN
4 Director-Division of Endocrinology, KHS-MRC, IN
1 Senior Research Fellow, Kasturba Health Society Medical Research Centre (KHS-MRC), IN
2 Physician, KHS-MRC, IN
3 Director-Integrative Medicine and Clinical Research, KHS-MRC, IN
4 Director-Division of Endocrinology, KHS-MRC, IN
Source
The Indian Practitioner, Vol 76, No 2 (2023), Pagination: 21-25Abstract
Background and Aims: Non-Alcoholic Fatty Liver Disease (NAFLD) includes a wide spectrum of liver pathophysiology, ranging between relatively benign Nonalcoholic fatty liver to a serious pathology like fibrosis and cirrhosis. NAFLD is commonly associated with Type 2 Diabetes Mellitus (T2DM) and Metabolic Syndrome and may increase the risk for mortality. American Diabetes Association and European Association for the study of Diabetes have recommended screening of all T2DM patients for NAFLD.
Materials and Methods: We did a retrospective analysis of medical records of T2DM patients who attended a diabetes clinic as ambulant patients for 1 year. Out of 215 patients, complete demographic, haemodynamic and biochemical data was available for 46 patients. Simple liver indices like Hepatic Steatosis Index (HSI) and Fibrosis score (FIB-4) were computed.
Results: Presence of steatosis was observed in30 patients based on HSI > 36. Out of these, intermediate risk of advanced fibrosis was observed in 4 patients based on FIB-4 > 1.3.
Conclusion: HSI based screening for steatosis and FIB-4 based screening for fibrosis should be part of liver monitoring in patients with type 2 diabetes mellitus to identify individuals with higher risk for NAFLD.
Keywords
Hepatic Steatosis Index, Fibrosis Score, Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis.References
- Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J. Ophthalmol 2021; 69:2932-8.
- Mitra S. Diabetes Research, Prevalence, and Intervention in India. European Journal of Environment and Public Health 2019, 3(1), 1-5. Available at, http://dx.doi.org/10.20897/ejeph/4004
- Dharmalingam M and Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.Indian J Endocrinol Metab. 2018; 22(3): 421-428.doi: 10.4103/ijem.IJEM_585_17, PMCID: PMC6063173PMID: 30090738
- Weiti Wu, Jingjing Xiang, Xiaoye Chen, Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals with Ultrasound-Defined Non-Alcoholic Fatty Liver Disease. 2021; 12:773342, doi: 10.3389/fendo.2021.773342, PMID: 34992579, PMCID: PMC8724262
- De A, Duseja A, Nonalcoholic Fatty Liver Disease: Indian Perspective. Clinical Liver Disease September 2021; 18 (3): 158-163.
- Sumida Y, Nakajima A, Hyogo H, Tanaka S, Ono M, Fujii H, et al. Non-invasive scoring systems for predicting NASH in Japan: evidence from Japan Study Group of NAFLD. Integr Mol Med 2015: 2(2): 145-149. doi: 10.15761/IMM.1000130
- Dhamija, E, Paul, SB, Kedia, S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. The Indian journal of medical research 2019; 149(1): 9-17. https://doi.org/10.4103/ijmr.IJMR_1456_17
- Viswanathan V, Kadiri M, Medimpudi S, Kumpatla S, Association of non-alcoholic fatty liver disease with diabetic microvascular and macrovascular complications in south Indian diabetic patients. International Journal of Diabetes in Developing countries. 2010; 30(4): 208-212.
- Barbosa JV, Lai M. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. Hepatology Communications 2021; 5(2):158-167. https://doi.org/10.1002/hep4.1618
- Adams LA, Lymp JF, St Sauver J, et al. The natural history of non alcoholicfatty liver disease: a population-based cohort study. Gastroenterology2005; 129:113-21.
- Arslan U, Turkoglu S, Balcioglu S, et al. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 2007; 18:433-6.
- Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, KimW,et al. Hepatic Steatosis Index: A simple screening tool reflectingnonalcoholic fatty liver disease. Digestive and Liver Disease 2010; 42(7): 503-508.doi: 10.1016/j.dld.2009.08.002
- Fennoun H, Mansouri SE, Tahiri M, Haraj NE, Aziz SE, Hadad F, et al. Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes. Pan Afr Med J. 2020; 37: 270.doi: 10.11604/pamj.2020.37.270.9087, PMCID: PMC7864273, PMID: 33598084
- Lomonaco R, LeivaEG,Bril F, Shrestha S, MansourL,Budd J et al. Advanced Liver Fibrosis IsCommon in Patients with Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care 2021; 44:399-406 | https://doi.org/10.2337/dc20-1997
- Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. ‘FIB-4: an Inexpensive and Accurate Marker of Fibrosis in HCV Infection. Comparison with Liver Biopsy and FibroTest. Hepatology 2007; 46 (1): 32-36.
- Rinella ME. Nonalcoholic fatty liver disease: Asystematic Review. JAMA, 2015; 313: 2263-73.
- Nanji AA, French SW, Freeman JB. Serum alanine amino transferase to aspartate amino transferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 1986; 36: 266-9.
- Long MT, Pedley A, Colantonio LD, Massaro JM, Hoffmann U, Muntner P et al. Development and validation of the Framingham Steatosis index to identify persons with hepatic steatosis. Clin Gastroenterol Hepatol, 2016; 14: 1072-1180.
- Ken Liu K, Xu W, Vincent Wai-Sun Wong. Serum biomarkers for nonalcoholic fatty liver disease: Are we there yet? Hepatology. 2017; 65(1): 8-11. doi: 10.1002/hep.28840. PMID: 27639247 DOI: 10.1002/hep.28840
- Sberna AL, B. Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, Duvillard L, Denimal D, Loffroy R, Verges B, Hillon P, Petit M. European Association for the Study of the Liver (EASL),European Association for the Study of Diabetes (EASD),and European Association for the Study of Obesity (EASO), clinical practice recommendations for the managementof non-alcoholic fatty liver disease: evaluation of their application in peoplewithType2diabetes.https://www.researchgate.net/profile/Jean-Michel-Petit/publication/321862648_ Diabet. Med. 00: 000–000 (2018)
- Shah AG, LydeckerA, Murray K, Tetri BN, ContosMJ, Sanyal AJ, and NASH Clinical Research Networket. Use of the fib4 index for non-invasive evaluation of fibrosis in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 October; 7(10): 1104–1112. doi: 10.1016/j.cgh.2009.05.033.
- Training Program for Good Clinical Practices
Abstract Views :53 |
PDF Views:0
Authors
Affiliations
1 Deputy Director, Knowledge Cell, Kasturba Health Society’s Medical Research Centre (KHS-MRC), IN
2 Director, Clinical Research & Integrative Medicine and Joint Research Head, KHS-MRC, Mumbai, IN
1 Deputy Director, Knowledge Cell, Kasturba Health Society’s Medical Research Centre (KHS-MRC), IN
2 Director, Clinical Research & Integrative Medicine and Joint Research Head, KHS-MRC, Mumbai, IN